Design, Setting, and Participants
Interventions and Main Outcome Measures
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Pediatric and Adolescent Gynecology
- U.S. medical eligibility criteria for contraceptive use, 2016.MMWR Recomm Rep. 2016; 65: 1
- Sexual activity, contraceptive use, and childbearing of teenagers aged 15-19 in the United States.NCHS Data Brief. 2015; 209: 1
- Sexual activity and contraceptive use among teenagers in the United States, 2011-2015.Natl Health Stat Rep. 2017; 104: 1
- Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and Gynecologists: Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices.Obstet Gynecol. 2012; 120: 983
- Long-acting reversible contraception for adolescents and young adults: patient and provider perspectives.J Pediatr Adolesc Gynecol. 2013; 26: 86
- Reducing pain during intrauterine device insertion: a randomized controlled trial in adolescents and young women.Obstet Gynecol. 2017; 130: 795
- An ultra-brief screening scale for anxiety and depression: the PHQ-4.Psychosomatics. 2009; 50: 613
- Effects of prophylactic misoprostol administration prior to intrauterine device insertion in nulliparous women.Contraception. 2011; 84: 234
- Lidocaine 10% spray to the cervix reduces pain during intrauterine device insertion: a double-blind randomised controlled trial.J Fam Plann Reprod Health Care. 2016; 42: 83
- Higher dose cervical 2% lidocaine gel for IUD insertion: a randomized controlled trial.Contraception. 2013; 88: 730
- Sublingual misoprostol prior to insertion of a T380A intrauterine device in women with no previous vaginal delivery.Eur J Contracept Reprod Health Care. 2013; 18: 300
- Pain control for intrauterine device insertion: a randomized trial of 1% lidocaine paracervical block.Contraception. 2012; 86: 704
- Using an age-specific nursing model to tailor care to the adolescent surgical patient.AORN J. 2014; 99: 733
A.Y. Akers is a consultant for the Merck HPV advisory board, and received less than $5000.00 in 2017 and anticipates receiving less than $10,000.00 in 2018. She is a member of the Reproductive Health Professionals HPV Advisory Board and receives less than $5000.00 annually ($2500.00 in 2016), did not receive money in 2017, and anticipates receiving less than $5000.00 in 2018. She is also a speaker for the Adolescent Reproductive and Sexual Health Education Project and she receives less than $5000.00 annually for this relationship. L.K. Perriera has been a consultant to Merck who trains health care providers to insert the Nexplanon contraceptive device, and receives less than $5000.00 annually. C.A. Schreiber receives research support from Medicines360 and Contramed. She served as a consultant for Berlex Pharmaceuticals in 2016. S. Sonalkar has been a consultant to the World Health Organization and is supported by the National Institutes of Health, United States Women's Reproductive Health Research Career Development Program (K12-HD001265-19). The remaining authors indicate no conflicts of interest.
This study is registered at Clinicaltrials.gov (NCT02352714).